文献速递前列腺癌

一线阿比特龙治疗的转移性去势抵抗性前列腺癌患者进展后接受立体定向体部放疗的影响:ARTO试验亚组分析

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-02-19

ARTO试验的II期随机试验提示,在寡转移性去势抵抗性前列腺癌中,阿比特龙醋酸泼尼松联合立体定向体部放疗的同期治疗策略可能获益。本分析按首次进展后实际治疗分组,A组接受寡进展灶SBRT,B组接受二线全身治疗,比较PFS1+PFS2和OS,两组无显著差异。

要点

  • 首次进展后接受SBRT者(A组)与接受二线全身治疗者(B组)的PFS1+PFS2无显著差异。
  • A组中位PFS1+PFS2为45.9个月,B组未达到,HR 0.63,95%CI 0.17-2.33,P=0.489。
  • 两组中位OS均未达到,实验组有非显著获益趋势,HR 0.50,95%CI 0.14-1.78,P=0.284。

核心结论

  • 本分析结果显示,对于寡转移性去势抵抗性前列腺癌,进展后接受SBRT与二线全身治疗相比,可能是一种可行且可实施的选项。

研究设计与样本

  • ARTO试验(NCT03449719)为II期随机试验,本分析纳入其中报告首次进展事件的患者,按首次进展后实际接受的治疗分为A组(寡进展灶SBRT,n=43)和B组(二线全身治疗,n=20),不考虑初始随机分组。
  • PFS1定义为阿比特龙开始至首次进展事件的时间,PFS2定义为首次进展至第二次进展、死亡或末次随访(以先发生者为准)的时间。
  • 采用Cox回归分析比较A组与B组的PFS1+PFS2,采用Kaplan-Meier分析比较两组总生存。

主要发现

  • A组(n=43)中位PFS1+PFS2为45.9个月,B组(n=20)未达到,HR 0.63,95%CI 0.17-2.33,P=0.489,未检测到显著差异。
  • 两组中位OS均未达到,实验组有非显著获益趋势,HR 0.50,95%CI 0.14-1.78,P=0.284。

关键数值与推荐

  • A组中位PFS1+PFS2为45.9个月,B组未达到(HR 0.63,95%CI 0.17-2.33,P=0.489)。
  • 两组中位OS均未达到(HR 0.50,95%CI 0.14-1.78,P=0.284)。

临床怎么用

  • 原文结论认为,对于寡转移性去势抵抗性前列腺癌,进展后接受SBRT与二线全身治疗相比,可能是一种可行且可实施的选项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate resistant prostate cancer (omCRPC). The object of the current analysis is to explore whether the benefit provided by SBRT to AAP is maintained at later stages of disease after oligoprogression METHODS: Patients enrolled in ARTO trial in whom a first progression event was reported were divided in two groups according to the treatment approach received, regardless of the initial randomization. After first progression event, Patients in Group A received SBRT on oligoprogressive disease, while patients in group B received second line systemic treatment. Palliative RT was not considered for the purpose of this analysis. Progression-Free survival (PFS) 1 and 2 were defined as time between AAP start and first progression event and time between first and second progression event, death or last follow up, (whichever came first), respectively. Cox regression analysis was performed to compare PFS1 + PFS2 in patients in group A vs Group B. Kaplan-Meier analysis was performed to compare overall survival between the two groups RESULTS: Median PFS1 + PFS2 was 45.9 months vs. not reached in group A (n = 43) vs Group B (n = 20), respectively (HR 0.63, 95% CI 0.17-2.33, p value 0.489), no significant difference was detected. Median OS was not reached in neither of the two arms of treatment, with a non-significant trend in favour of the experimental arm (HR 0.50, 95% CI 0.14-1.78, p = 0.284) CONCLUSIONS: Results from the present analysis show that SBRT after progression may be a viable and feasible option for omCRPC after progression if compared to second line systemic therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Francolini G, Bertini N, Di Cataldo V, et al. Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719). Prostate Cancer Prostatic Dis. 2025. PMID: 39972049. doi:10.1038/s41391-025-00950-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。